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Suppression of mitochondrial function promoting
proliferation and apoptosis suppression has been
described in the pulmonary arteries and extrapul-
monary tissues in pulmonary arterial hypertension
(PAH), but the cause of this metabolic remodeling
is unknown. Mice lacking sirtuin 3 (SIRT3), a mito-
chondrial deacetylase, have increased acetylation
and inhibition of many mitochondrial enzymes and
complexes, suppressing mitochondrial function.
Sirt3KO mice develop spontaneous PAH, exhibiting
previously described molecular features of PAH
pulmonary artery smooth muscle cells (PASMC). In
human PAH PASMC and rats with PAH, SIRT3 is
downregulated, and its normalization with adeno-
virus gene therapy reverses the disease phenotype.
A loss-of-function SIRT3 polymorphism, linked to
metabolic syndrome, is associated with PAH in an
unbiased cohort of 162 patients and controls. If
confirmed in large patient cohorts, these findings
may facilitate biomarker and therapeutic discovery
programs in PAH.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a deadly disease char-
acterized by obliterative vascular remodeling due to increased
proliferation and suppressed apoptosis in the resistance pulmo-
nary artery (PA) vascular cells. Suppression in mitochondrial
function (and specifically glucose oxidation [GO]) of PA smooth
muscle cells (PASMCs) and endothelial cells, leads to compen-
satory upregulation of glucose uptake and glycolysis (Gly) in a
manner similar to cancer (Archer et al., 2008; Kluge et al.,
2005; Sutendra and Michelakis, 2014; Xu et al., 2007; Zhao
et al., 2013). This mitochondrial suppression underlies in part
the inhibition of mitochondria-dependent apoptosis (Sutendra
and Michelakis, 2014). Additionally, downstream mitochondrial
signaling promotes the activation of proproliferative and antia-
poptotic transcription factors that are important in human andCell Manimal PAH, including the nuclear factor of activated T cells
(NFAT) (Bonnet et al., 2007b), signal transducer and activator
of transcription 3 (STAT3) (Paulin et al., 2011), and hypoxia
inducible factor-1a (HIF-1a) (Bonnet et al., 2006). Mitochondrial
reactivation has shown promise as therapeutic strategy in animal
models in both PAH and cancer (Bonnet et al., 2007a; McMurtry
et al., 2005). However, the primary cause of this mitochondrial
suppression is unknown.
Similar metabolic abnormalities also exist in extravascular tis-
sues in PAH patients. In the absence of obesity or diabetes,
many PAH patients have evidence of insulin resistance with a
‘‘metabolic syndrome-like’’ clinical picture, the presence of
which is associated with worse clinical outcomes (Hansmann
et al., 2007; Pugh et al., 2011; Zamanian et al., 2009). Insulin
resistance in skeletal muscle of patients with metabolic syn-
drome and type II diabetes is associated with suppressed oxida-
tive phosphorylation and mitochondrial function (Petersen et al.,
2004; Simoneau and Kelley, 1997). This raises the possibility that
a global mitochondrial abnormality may exist in PAH patients
(Sutendra and Michelakis, 2014).
The mitochondria-localized deacetylase Sirtuin 3 (SIRT3) reg-
ulates many levels of mitochondrial function by deacetylating
and thus activating multiple enzymes and electron transport
chain (ETC) complexes; leading to impaired oxidative phosphor-
ylation and a compensatory increase in glucose uptake and
glycolysis (Finley et al., 2011b; Hirschey et al., 2011; Lombard
et al., 2007; Zhao et al., 2010). SIRT3 acts as a tumor suppres-
sor, and its expression is decreased in human cancers,
while its absence promotes cancer in mice (Finley et al.,
2011a; Kim et al., 2010). Furthermore, a SNP in the SIRT3
gene (rs11246020) within the conserved catalytic deacetylase
domain, leads to a 30% decrease in enzymatic activity and
is associated with the development of metabolic syndrome in
humans (Hirschey et al., 2011).
We hypothesized that suppressed SIRT3 function (because
of decreased expression, decreased enzymatic function due
to loss-of-function SNPs, or both) promotes PAH and may
explain the diverse metabolic abnormalities in this disease,
potentially identifying this mitochondrial protein as a biomarker
and therapeutic target. We tested our hypothesis in rodent
models of PAH, in human PAH tissues, and explored the fre-
quency of the rs11246020 SNP in a cohort of 162 PAH patients
and controls.etabolism 20, 827–839, November 4, 2014 ª2014 Elsevier Inc. 827
Figure 1. Sirt3 Deficiency Suppresses Mitochondrial Function in Pulmonary Artery Smooth Muscle Cells
(A) Immunoblots on isolated mitochondria showing the level of SIRT3 protein and acetyl-lysine in WT and KO-PASMCs at basal conditions (normoxia, 21% O2)
and under moderate or severe hypoxia. The mitochondrial protein COX4 is used for normalization.
(B) Representative MitoProfile dipstick assays on PASMCs and mean data of PDH activity (n = 3 experiments/group, ***p < 0.001).
(C) Mean data of Sirt3WT and KO-PASMCs oxygen consumption rate measured by an oxygen electrode, showing that lack of SIRT3 causes a significant
suppression of PASMCs respiration (n = 5/group, **p < 0.01).
(D) Krebs’ cycle metabolites levels measured bymass spectroscopy (n = 3merged samples/group) in normoxic and hypoxic Sirt3WT and KOPASMC; results are
expressed as % decrease compared to normoxic Sirt3WT.
(E) a-KG levels, measured by colorimetric assay, are decreased in the Sirt3KO PASMC (n = 3 experiments/group, ***p < 0.001).
(F) Representative confocal images and mean data of mitochondrial membrane potential (DJm) measured by the positively charged dye TMRM in live PASMCs;
nuclei are stained blue by Hoechst (n = 150 cells/group, p < 0.05 compared to normoxic Sirt3WT PASMCs).
Error bars represent SEM.
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Pulmonary Artery Smooth Muscle Cells Lacking Sirt3
Have Suppressed Mitochondrial Function
We first established lines of PASMCs isolated from resistance
PAs from Sirt3 wild-type (Sirt3WT) and knockout (Sirt3KO)
mice. Genotyping of Sirt3WT and KO mice, quantitative real-
time (qRT)-PCR and immunoblots in PASMCs confirmed the
absence of Sirt3 mRNA and SIRT3 protein in the Sirt3KO tis-
sues (Figure 1A and Figure S1A available online). To explore
the magnitude of the mitochondrial changes, we compared nor-
moxic (21% oxygen) Sirt3KO-PASMCs with hypoxic Sirt3WT-
PASMCs exposed to hypoxia, which suppresses mitochondrial
oxidative phosphorylation.We speculated that whether themito-
chondrial suppression is due to an intrinsic parameter (lack of828 Cell Metabolism 20, 827–839, November 4, 2014 ª2014 ElsevierSIRT3) or lack of oxygen, the effects on global mitochondrial
function might be similar. Compatible with the loss of deacety-
lase activity, isolated mitochondria from Sirt3KO-PASMCs
had increased levels of protein lysine-acetylation compared to
Sirt3WT-PASMCs (Figure 1A). We also found that a similar in-
crease in the acetylation profile was present in mitochondria
from Sirt3WT-PASMCs exposed to either moderate (4% O2) or
severe (1% O2) hypoxia. Exposure to hypoxia also caused a
decrease in SIRT3 protein levels. A similar decrease in SIRT3
levels has been described in a variety of diseases, including can-
cer (Finley et al., 2011a; Kim et al., 2010).
In general, increased acetylation is associated with decreased
enzymatic and ETC complex activity in mitochondria (He et al.,
2012). We directly measured the enzymatic activity of the mito-
chondrial enzyme pyruvate dehydrogenase (PDH), the functionInc.
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muscle (Jing et al., 2013). PDH is a gate-keeping enzyme for GO
in the mitochondria, converting pyruvate into acetyl-CoA, which
then feeds into the Krebs’ cycle. PDH inhibition exists in several
models of PAH and cancer and its reactivation (eithermolecularly
or by the small molecule dichloroacetate) reverses themitochon-
drial suppression and established disease (Michelakis et al.,
2010; Sutendra and Michelakis, 2013). However, the primary
cause of PDH inhibition remained unclear. We found that nor-
moxic Sirt3KO-PASMCs had decreased PDH activity compared
toSirt3WT-PASMCs, and that this decreasewas similar to that of
hypoxic Sirt3WT-PASMCs (Figure 1B). In keeping, there was an
overall decrease in respiration (Figure 1C) and in the levels of all
tested Krebs’ cycle intermediates (measured by mass spectros-
copy) in the Sirt3KO-PASMCs compared to Sirt3WT-PASMCs
(Figure 1D). The percent decrease in metabolites was compara-
ble to that caused by hypoxia in Sirt3WT-PASMCs. Moreover,
hypoxia did not cause a significant further decrease in themetab-
olites inSirt3KO-PASMCs (Figure 1D). The decrease in the diffus-
ible metabolite a-ketoglutarate (a-KG) in Sirt3KO-PASMCs was
confirmed by a colorimetric assay (Figure 1E).
Another global index of mitochondrial function is the mito-
chondrial membrane potential (DJm). H+ produced in the ETC,
as electrons derived from the Krebs’ cycle flow down its redox
gradient, along with the activity of the ATP synthase (which
brings H+ back into the mitochondrial matrix), contribute to this
electrochemical potential. Both the ETC complexes and ATP
synthase are deacetylated and activated by SIRT3 (Ahn et al.,
2008; Schlicker et al., 2008). PAH and hypoxic PASMC, as well
as many cancer cell lines, have increased DJm (Bonnet et al.,
2007b; Chen, 1988). We found that Sirt3KO-PASMCs had
increased DJm (compared to WT cells), and under physiologic
hypoxia (4% oxygen) Sirt3KO- and WT-PASMCs had similar
DJm (Figure 1F).
SIRT3mRNA levels were decreased in human idiopathic PAH
(iPAH)-hPASMCs (obtained from resistance PAs of a 34-year-old
female with iPAH) compared to normal hPASMCs (obtained from
resistance PAs of unused transplant material of a 29-year-old fe-
male) (Figure S1B). While very little is known on the mechanism
of Sirt3 transcription regulation, PGC-1a can activate Sirt3
gene expression through coactivation of the orphan nuclear es-
trogen-related receptor-a (ERR-a), which binds the proximal
Sirt3 promoter region (Giralt et al., 2011). We thus measured
the mRNA levels of PGC-1a in normal and iPAH-PASMCs. We
found an impressive decrease in PGC-1a mRNA in iPAH-
hPASMCs compared to normal cells (Figure S1B). This is in
keeping with Mata et al. (Mata et al., 2012) who showed that in
the blood of PAH patients, decreased levels of PGC-1a expres-
sion are associated with higher PA pressures, and Ryan et al.
(Ryan et al., 2013) who showed decreased levels of PGC-1a in
rodent and human PAH PASMC. We then transfected Sirt3WT
PASMCs with siRNA directed against PGC-1a and found that
80% decrease in PGC-1a was associated with 70% decrease
in the mitochondrial protein level of Sirt3 (Figure S1C). This sug-
gests that PGC-1a is responsible, at least in part, for the down-
regulation of Sirt3 in PAH.
As inmouseSirt3KO-PASMCs, knockdown ofSIRT3 in normal
hPASMC increased DJm; and knockdown of SIRT3 in iPAH-
hPASMCs decreased respiration (Figures S1D and S1E). Adeno-Cell Mvirus mediated overexpression of SIRT3 and GFP (AdSIRT3) in
iPAH-hPASMCs restored respiration and normalized DJm
compared to cells infected with an adenovirus expressing only
GFP (AdGFP) (Figures S1D and S1E), showing that rescue of
SIRT3 deficiency is enough to normalize mitochondrial function
(cellular respiration and DJm). We were able to specifically
show the effects of the adenoviral infection in hPASMC by imag-
ing both GFP (marking the successfully infected cells; thick
arrowhead, versus the noninfected cells; thin arrowhead) and
tetramethyl rhodamine methyl ester (TMRM) (a DJm-sensitive
dye) under the same conditions (Figure S1E). These data sug-
gested that adenoviral mediated correction of SIRT3 deficiency
can be explored as a therapeutic tool, an approach that we
follow later on.
Activation of Several Transcription Factors Critical for
Pulmonary Arterial Hypertension in Sirt3knockout-
Pulmonary Artery Smooth Muscle Cells
Although HIF-1a can suppress mitochondrial function by down-
regulating several mitochondrial proteins, the opposite has also
been described, where diffusible mitochondrial mediators like
a-KG can directly regulate and inhibit HIF-1a since it is a required
cofactor for HIF-1a prolyl-hydroxylases, and its decrease pro-
motes HIF-1a stabilization (MacKenzie et al., 2007; Sutendra
et al., 2013). Therefore, we assessed HIF-1a activity in our model
where a-KG is decreased (Figure 1E), using immunofluores-
cence, immunoblots, and a dual-luciferase reporter assay.
Sirt3WT-PASMCs exposed to hypoxia exhibited the expected
increase in HIF-1a activity (Figure 2A). However, Sirt3KO-
PASMCs showed activation of HIF-1a even in normoxia, and
the addition of hypoxia did not further increase HIF-1a activity,
suggesting maximal normoxic activation. Normoxic Sirt3KO-
PASMCs also showed increased expression of the HIF-1a target
genes PDH kinase 1 (Pdk1) and vascular endothelial growth
factor a (Vegfa) compared to Sirt3WT-PASMCs (Figure 2A). We
then exposed Sirt3KO-PASMCs to a cell-permeable form of
a-KG (MacKenzie et al., 2007; Sutendra et al., 2013) and found
that a-KG normalized the suppressed hydroxylation of HIF-1a,
resulting in decreased HIF-1a nuclear levels, transcriptional
activity, and target gene expression (Figure 2B).
Sirt3KO-PASMCs had increased phosphorylation of STAT3 at
tyrosine 705, which promotes STAT3 nuclear translocation
(Paulin et al., 2011) (Figure 3A). Exploring the mechanism of this
first-description of STAT3 activation by loss of SIRT3, we studied
the ETC-complex I subunit Retinoid-Interferon-induced Mortal-
ity-19 (GRIM-19), that acts as a chaperone to recruit STAT3 into
mitochondria (Shulga and Pastorino, 2012). Mitochondrial
STAT3 is ‘‘protected’’ from phosphorylation on Y705 in the cyto-
plasm. Sirt3WT-PASMCs showed STAT3 partially colocalizing
with the mitochondrial marker Mitotracker. This pattern was
lost in Sirt3KO-PASMCs, where STAT3 was mostly localized in
the nucleus (Figure 3A). We speculated that the inhibition of
ETC-complex I by the loss of Sirt3 contributes to the lack of
integration of GRIM-19 (and thus STAT3) into the mitochondria,
since rotenone, an ETC-complex I inhibitor, promotes nuclear
translocation of GRIM-19 (Reeves et al., 2007). We found that
while GRIM19 is strictly localized in mitochondria in Sirt3WT-
PASMCs, it is partially displaced to nuclei of Sirt3KO-PASMCs
or rotenone-treated Sirt3WT-PASMCs (Figure S2A). In stainingetabolism 20, 827–839, November 4, 2014 ª2014 Elsevier Inc. 829
Figure 2. Sirt3KO Pulmonary Artery Smooth Muscle Cells Have HIF-1a Activation even under Normoxia
(A) Left: immunoblots (representative gels and mean data) showing HIF-1a levels in normoxic and hypoxic Sirt3KO-PASMCs compared to WT-PASMCs (n = 3,
*p < 0.05 compared to normoxic WT-PASMCs). Representative confocal microscopy images and mean data showing HIF-1a (red) levels in nuclei stained with
DAPI (blue) (n = 150–200 cells/group, ***p < 0.001 compared to normoxic WT). Right: HIF-1a-driven luciferase signal compared between Sirt3WT and
KO PASMCs in normoxia and hypoxia, (n = 5 experiments/group, *p < 0.05 versus normoxic WT-PASMC). mRNA levels measured by qRT-PCR for HIF-1a
target genes pyruvate dehydrogenase kinase 1 (PDK1) and VEGFa in normoxic and hypoxic Sirt3WT and KO PASMCs (n = 3/group, ***p < 0.001 compared to
normoxic WT).
(B) Left: immunoblots (representative gels andmean data) showing hydroxylated (OH-) and total HIF-1a levels in Sirt3WT, Sirt3KO, and Sirt3KO-PASMCs treated
with a-KG (n = 3/group **p < 0.01 compared to normoxicWT ##p < 0.01 versus KO). In confocal imaging, nuclear HIF-1a is shown in red (nuclei stained in blue with
DAPI) in Sirt3WT, Sirt3KO, and Sirt3KO-PASMCs treated with a-KG (n = 150–200 cells/group, ***p < 0.001 compared to WT PASMCs, ##p < 0.01 versus KO).
Right: HIF-1a-driven luciferase signal and HIF-1a target genes PDK1 and VEGFamRNA level in Sirt3WT, Sirt3KO, and Sirt3KO-PASMCs treated with a-KG. (n = 3
experiments/group *p < 0.05, ***p < 0.001 compared to normoxic WT #p < 0.05 versus KO).
Error bars represent SEM.
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Insight into the Metabolic Basis of PAHPASMCwith both STAT3 andGRIM-19 antibodies, we found that
the cells showing the highest level of STAT3 in the nucleus also
show the highest nuclear levels of GRIM-19, whereas the cells
that showed no nuclear GRIM-19 also lacked nuclear STAT3.
Overall Sirt3KO-PASMCs had an increase in the nuclear and a
decrease in the mitochondrial levels of GRIM-19, while total
cellular GRIM-19 levels increased in Sirt3KO-PASMCs and rote-
none-treated Sirt3WT-PASMCs (Figures S2A and S2B). These
findings suggest that GRIM-19-dependent STAT3 activation is
due to inhibition of ETC-complex I. Furthermore, Sirt3KO-
PASMCs and rotenone-treated Sirt3WT-PASMCs had increased
expression of the STAT3 target genes (previously shown to830 Cell Metabolism 20, 827–839, November 4, 2014 ª2014 Elseviercontribute to PAH pathogenesis) Pim1 (Paulin et al., 2011) and
Survivin (Courboulin et al., 2011; McMurtry et al., 2005),
compared to Sirt3WT-PASMCs (Figure S2B).
Another master transcription factor implicated in PAH is NFAT.
The NFAT isoform NFATc2 regulates the transcription of many
glycolytic enzymes, inhibits the expression of Kv channels
(also a well described feature of PAH) (Yuan et al., 1998), pro-
motes proliferation, and inhibits apoptosis in PAH-PASMCs
(Bonnet et al., 2007b). Sirt3KO-PASMCs had increased expres-
sion and nuclear localization of NFATc2 (Figure 3B) compared to
Sirt3WT-PASMCs. NFATc2 is activated by STAT3 (Paulin et al.,
2011) as well as by decreased glycogen synthase kinase activityInc.
Figure 3. Sirt3KO Pulmonary Artery Smooth Muscle Cells Show Activation of STAT3 and NFATc2, Both Critical for Pulmonary Arterial
Hypertension Pathogenesis
(A) Left: immunoblots of both the phosphorylated form (on tyrosine 705, P-STAT3) and total form of STAT3 on Sirt3WT and KO-PASMCs. STAT3 activation is
expressed by the ratio P-STAT3/STAT3 normalized to smooth muscle actin level (n = 3, *p < 0.05). Right: representative confocal images and mean data of
PASMC positive for nuclear STAT3. Nuclear and mitochondrial staining was performed by DAPI and Mitotracker, respectively. Merged images show the nuclear
translocation of STAT3 in Sirt3KO PASMC (n = 150 cells/group, ***p < 0.001 compared to WT).
(B) Left: representative confocal images and mean data of immunostained NFATc2 in Sirt3WT and KO-PASMCs along with nuclear staining with DAPI (n = 150
cells/group, ***p < 0.001 compared with WT). Right: immunoblots of NFATc2 performed on Sirt3WT and KO-PASMCs. Mean data are expressed as a ratio over
SMA level, used as a loading control (n = 3, **p < 0.01). Both show activation of NFATc2 in Sirt3KO PASMC.
(C) Left: GSK-3b activation measured by immunoblots (ratio of phosphorylated form over total form) in Sirt3WT and KO PASMCs and normalized to SM-Actin.
Right: Representative confocal microscopy images and mean data showing Fluo3AM staining (green), measuring intracellular calcium levels; nuclei stained with
Hoechst 33342 (blue) (n = 150 cells/group, p < 0.001***). mRNA levels measured by qRT-PCR for the NFATc2 target gene Kcna5 (coding for the potassium
channel Kv1.5) showing a dramatic downregulation in Sirt3KO PASMC (n = 3/group, ***p < 0.001).
Error bars represent SEM.
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suppressed glucose oxidation in PAH and cancer) and by
increased intracellular Ca2+ levels (Macia´n et al., 2001; Pastorino
et al., 2005). We found that Sirt3KO-PASMCs had a slight in-
crease in phosphorylated (on Serine 9, i.e., inhibited) GSK-3b
(Figure 3C), in addition to a significant increase in intracellular
Ca2+ levels (Figure 3C). We also found a remarkable decrease
in the mRNA levels of the NFATc2 target gene KCNA5 (encoding
the voltage-gated potassium channel Kv1.5) in Sirt3KO-
PASMCs compared to Sirt3WT-PASMCs (Figure 3C). Interest-
ingly, this gene is also downregulated by activation of HIF-1aCell M(Bonnet et al., 2006), and thus the activation of both HIF-1a
and NFAT may explain its significant downregulation. As Kv1.5
regulates the resting plasma membrane potential in PASMC,
its loss or inhibition causes plasma membrane depolarization
and Ca2+ influx (Archer et al., 1998). Thus the resulting increase
in Ca2+ further enhances NFATc2 activation within a positive
feedback loop, contributing to its sustained activation, which
we now show may have a mitochondrial origin.
As expected by the activation of these three proprolifera-
tive and antiapoptotic transcription factors along with the
mitochondrial hyperpolarization, the Sirt3KO PASMC showedetabolism 20, 827–839, November 4, 2014 ª2014 Elsevier Inc. 831
Figure 4. Dynamic Regulation of STAT3, HIF-1a, and NFATc2 Activation by SIRT3
STAT3, HIF-1a, and NFATc2 activation, as well as proliferation and apoptosis, measured by nuclear translocation (confocal imaging), Ki67 expression, and
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) respectively, in normal (control) hPASMCs treated with Sirt3 siRNA (versus scrambled
siRNA) (left) and in iPAH-hPASMCs infected with Sirt3-adenovirus (versus adenovirus carrying only GFP) (right). The high efficiency of infection by the adenovirus
is shown by the GFP fluorescence in an example on the upper right panel (n = 150–200 cells/group, *p < 0.05, ***p < 0.001 versus CTRL, ##p < 0.01, ###p < 0.001
versus AdGFP). Error bars represent SEM.
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suppressed apoptosis in response to serum starvation,
compared to the WT PASMC (Figure S3A). Once again, hypoxia
did not further increase the proliferative potential of Sirt3KO-
PASMCs. Rescue experiments with AdSIRT3 infection of
Sirt3KO PASMC, in addition to normalizing DJm and respira-
tion (Figures S1D and S1E), decreased proliferation and
enhanced apoptosis (Figure S3).
To confirm the role of SIRT3 in human PASMC, we treated
normal hPASMCs with SIRT3 siRNA or infected iPAH-hPASMCs
with the AdSIRT3 (Figure 4). The nuclear levels of all three tran-
scription factors were increased following the downregulation
of SIRT3 in normal cells, confirming the results obtained in
mice cells and decreased following Sirt3 overexpression in
iPAH cells (Figure 4). Like in mice PASMC, Sirt3 gain of function
in AdSIRT3-infected iPAH-hPASMC decreased proliferation and
enhanced apoptosis (Figure 4).832 Cell Metabolism 20, 827–839, November 4, 2014 ª2014 ElsevierSirt3 Knockout Mice Develop Spontaneous Pulmonary
Arterial Hypertension
We then used right heart catheterization and echocardiography
to study Sirt3KO, heterozygote (Sirt3HET), and Sirt3WT mice.
The mice spontaneously developed PAH in a gene dose-depen-
dent manner. Sirt3KO, and to a lesser extent Sirt3HET mice, had
higher mPAP, total pulmonary resistance (TPR), right ventricular
hypertrophy, and impaired exercise tolerance compared to the
Sirt3WT controls at baseline, without differences in systemic
blood pressure or body weight (Figures 5A and S4A). Sirt3KO
mice, and to a lesser extent Sirt3HET mice, had increased mus-
cularization and medial wall thickness of resistance PAs
compared to the Sirt3WT controls at baseline (Figure 5B). These
results are consistent with the level of Sirt3 and the acetylation
status of mitochondrial proteins measured in the different geno-
types (Figure S4B), directly supporting a gene dose-dependent
effect (i.e., the lower the Sirt3 levels, the higher the mitochondrialInc.
Figure 5. Sirt3KO Mice Develop Spontaneous Pulmonary Arterial Hypertension in Gene Dose-Dependent Manner
(A) mPAP measured by right heart catheterization, right ventricular (RV) hypertrophy assessed by the ratio RV weight over left ventricle (LV)+septum weight and
TPR (TPR = mPAP/CO) in Sirt3WT, HET, and KO mice (n = 9/group, **p < 0.01, ***p < 0.001).
(B) Representative H&E staining showing vascular remodeling andmean data of medial wall thickness, resistance PAmuscularization, and proliferation assessed
by Ki67 staining of lung sections of Sirt3WT, HET, and KO mice. The confocal images to the right with costaining with smooth muscle actin and Ki67 antibodies,
localize the proliferation (Ki67 expression) within the media of resistance pulmonary arteries (nuclei blue with DAPI); (n = 100 vessels/animal, 5 animals/group,
*p < 0.05, **p < 0.01, ***p < 0.001 compared to WT mice).
Error bars represent SEM.
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Insight into the Metabolic Basis of PAHacetylation, the worse the pulmonary hypertension). Further-
more, smooth muscle actin-positive (SMA+) resistance PASMCs
had increased proliferation markers (Ki67) (Figure 5B) and
increased NFATc2 and HIF-1a nuclear levels (Figure S4C),
consistent with the in vitro findings.
We then performed oil-red staining on skeletal muscle sec-
tions and found a significant accumulation of lipid droplets in
Sirt3KO, but not Sirt3WTmice muscle, an indication of dysregu-
lated mitochondrial fatty acid oxidation, typically used as an in-
dex of insulin resistance in mice (West et al., 2013) and humans
(Petersen et al., 2004; Simoneau and Kelley, 1997) (Figure S4D).
Sirt3 Can Be Therapeutically Targeted in a Standard
Model of Rat Pulmonary Arterial Hypertension
To determine whether SIRT3 expression is reduced in a standard
animal PAH model, we used the monocrotaline (MCT)-induced
PAH rat model. After PAH was established (3 weeks post MCT
injection), we measured PGC-1a and Sirt3 mRNA levels byCell MqRT-PCR in whole lung and laser-captured resistance PAs and
found decreased levels for both (Figures 6A and S5A). In isolated
mitochondria from intrapulmonary PAs we found decreased pro-
tein expression of SIRT3, associated with an increase in mito-
chondrial protein acetylation (Figure 6B).
PGC-1a and Sirt3 expression was also decreased in the hy-
pertrophied right ventricle (RV) of MCT-PAH rats compared to
controls, but not in the corresponding left ventricles (Figure S5B).
PGC-1a colocalized with nuclei of cardiomyocytes (stained for
Myosin Heavy Chain) in control RVs, but not in MCT-PAH RVs
(Figure S5C).
We then performed gene therapy in order to restore SIRT3
expression/function and reverse established PAH. We have pre-
viously elicited a biological effect in resistance PAs using gene
therapy with an inhaled adenovirus approach (McMurtry et al.,
2005; Paulin et al., 2011). Rats received intratracheal delivery
of either an adenovirus (3 3 109 plaque-forming unit [pfu]/rat)
carrying the GFP gene alone (AdGFP) or GFP+Sirt3 genesetabolism 20, 827–839, November 4, 2014 ª2014 Elsevier Inc. 833
Figure 6. Rescue Sirt3 Gene Therapy Restores SIRT3 Levels in Resistance Pulmonary Arteries and Reverses Rat Pulmonary Arterial Hyper-
tension
(A) On the left, pictures of a lung sample before and after laser captured microdissection (LCM) of a small PA sample, and on the right a picture of the dissected
vessel trapped on the cap and processed for RNA extraction. PGC-1a gene (Ppargc1a) and Sirt3 levels were measured by qRT-PCR after LCM on control and
Monocrotaline (MCT) treated rats (n = 5, **p < 0.01).
(B) Immunoblots performed on isolated mitochondria from resistance pulmonary arteries of controls and rats with MCT-PAH. Levels of SIRT3 (decreased) and
lysine acetylation (increased) were normalized to the mitochondrial marker COX4 (n = 3, **p < 0.01).
(C) mPAP, medial wall thickness, and TPR measured after 2 weeks of adenovirus-mediated Sirt3 gene therapy (total of 5 weeks post MCT injection) (n = 5 rats/
group, *p < 0.05, **p < 0.01, ***p < 0.001 versus control rats; ##p < 0.01, ###p < 0.001 versus MCT-PAH+AdGFP).
(D) Representative confocal images from lung sections ofMCT-PAH andMCT-PAH+AdSIRT3. Vessels were visualized by SMA (pink), vonWillebrand Factor (vWF;
red), and nuclei were stained blue by DAPI. The GFP fluorescence shows the effective infection of small pulmonary arteries after inhaled gene therapy.
(E) Sirt3mRNA expression measured by qRT-PCR after resistance PA LCM (n = 5, ###p < 0.001MCT-PAH+AdSIRT3 versusMCT-PAH+AdGFP) and immunoblots
performed on isolated mitochondria from resistance pulmonary arteries of MCT-PAH+AdGFP and MCT-PAH+AdSIRT3 rats. SIRT3 protein expression was
normalized to COX4 (n = 3, #p < 0.05).
(F) Proliferation (%Ki67) was decreased and apoptosis (%TUNEL) was increased in pulmonary arteries (stained with SM-actin) of rats treated with adenovirus.
(n = 10–20 arteries/rat, 5 rats/group, ###p < 0.001 versus MCT-PAH+AdGFP).
Error bars represent SEM.
Cell Metabolism
Insight into the Metabolic Basis of PAH(AdSIRT3) 3 weeks post MCT injection and were followed up for
two additional weeks. AdSIRT3-treated rats had significant
improvement in the mPAP, TPR, and exercise tolerance, and
decreased medial wall thickness compared to the AdGFP-
treated rats (Figures 6C and S5E). GFP was detected throughout
the vascular wall of remodeled resistance PAs (<50 mm), sug-
gesting a good distribution of the nebulized viruses in the pulmo-
nary circulation (Figure 6D). We also found increased levels of834 Cell Metabolism 20, 827–839, November 4, 2014 ª2014 ElsevierSIRT3 (qRT-PCR on laser-capture microdissection samples
and western blots on resistance PAs) in the AdSIRT3 treated
rats, even 2 weeks postnebulization suggesting a sustained
expression of the transgene and supporting the hemodynamic
improvement during that period (Figure 6E). Finally, AdSirt3
treatments were associated with decreased levels of prolife-
ration and increased levels of apoptosis of SMA-positive
cells in resistance PAs (Figures 6F and S5E), explaining theInc.
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treated rats.
The SIRT3 Loss-of-Function Polymorphism rs11246020
Is Associated with Human Idiopathic Pulmonary Arterial
Hypertension
Since SIRT3 SNPs have been associated with human disease,
we tested whether the previously described SNP rs11246020
(associated with a 30% decrease in SIRT3 activity and the
presence of clinical metabolic syndrome) (Hirschey et al., 2011)
was overrepresented in an unbiased cohort of 162 patients
(consecutive referrals) from our PAH clinics. The patients had
either idiopathic PAH (iPAH, n = 49, mean age 46, and 68% fe-
male) or PAH associated with collagen vascular disease or
congenital heart disease (aPAH, n = 64, mean age 57, and
81% female). The diagnosis of PAH was established following
a standard clinical workup, which included right heart catheteri-
zation in all patients.We also studied blood samples from normal
volunteers or patients that proved to have no PAH after complete
workup (noPAH, n = 49, mean age 48, and 80%female). Some of
these patients underwent transplantation, allowing for lung tis-
sue studies. All patients were > 18 years old.
The frequency of SNP homozygosity (HOM, i.e., AA) and het-
erozygosity (HET, i.e., AG) in the noPAH group was 6.12% and
22.45%, respectively; the normal genotype (WT; i.e., GG) being
predominant (71.42%). Similar results were obtained in aPAH
(1.56% HOM, 26.56% HET, and 71.88% WT). In iPAH however,
the frequency of SNP homozygosity and heterozygosity reached
16.32% and 46.94%, respectively; the normal (WT) phenotype
reaching only 36.73%. A Pearson chi-square test showed an as-
sociation between iPAH and the presence of the SNP with a p
value < 0.001 (Figure 7A). We then used 15 lung transplant tissue
samples (three unused normal, eight iPAH, and four aPAH) for
which we determined the genotype, assessed the histology by
hematoxylin and eosin (H&E) staining in order to confirm the
classic pathology findings of PAH (Figure 7C), and isolated mito-
chondria to evaluate SIRT3 expression and mitochondrial pro-
tein acetylation (Figure 7B). As in isolated iPAH-hPASMCs, we
found a decrease in the level of SIRT3 measured by qRT-PCR
and immunoblots in iPAH compared to noPAH patients (Fig-
ure 7B). The presence of the SNP (in either homozygote or het-
erozygote manner) in iPAH patients was associated with
increased acetylation of mitochondrial proteins compared to
the iPAH patients with the normal genotype (WT) or to the noPAH
patients (Figure 7B). These data suggest that SIRT3 activity in
iPAH-PASMC is suppressed due to either a downregulation of
the expressed protein or the presence of a loss-of-function
SNP or both. On the other hand, similar to the frequency of the
SIRT3 SNP, we did not find any significant differences in the
levels of Sirt3 in the aPAH compared to the noPAH patients
(Figure 7B).
DISCUSSION
Here we show that SIRT3 is a critical regulator of metabolic ho-
meostasis in PASMCs, and that loss of SIRT3 function promotes
the development of PAH. Decreased SIRT3 expression and/or
activity is associated with mitochondrial suppression, inhibition
of mitochondria-dependent apoptosis, and activation of severalCell Mproproliferative transcription factors, enhancing vascular remod-
eling and PAH development (Figure 7D). We also found indirect
indices of insulin resistance in Sirt3KO skeletal muscle, in agree-
ment with the metabolic syndrome-like features of PAH patients.
More importantly, we found that SIRT3 restoration in a rat PAH
model (as well as in mice Sirt3KO PASMC and in human iPAH-
hPASMC in vitro) attenuates the disease phenotype, identifying
SIRT3 as a potential therapeutic target. Finally, we found an
association between the presence of a SIRT3 SNP and iPAH in
humans, suggesting that SIRT3 loss of enzymatic function (in
addition to the decrease in SIRT3 expression) might be an
intrinsic factor predisposing to the development of human PAH
and a potential biomarker. Thus our work offers strong support
to the emerging metabolic theory of PAH (Archer et al., 2008; Su-
tendra and Michelakis, 2014; Xu et al., 2007).
This SIRT3 SNP association with PAH was not reported in a
recent genome-wide association analysis studying the associa-
tion of 472,421 SNPs in a sample of 340 idiopathic or familial
PAH cases and 1,068 controls of French origin (Germain et al.,
2013). The sensitivity of probe designs, cutoffs/filters used to
expose significant differences, or the particularly high frequency
of this SNP in the normal population (around 28% in our hands
for the total homozygote+heterozygote phenotype, similar to
what others have reported in studies ofmetabolic syndrome [Hir-
schey et al., 2011]) compared to the 63% frequency in our iPAH
patients, may explain this result; since the French study empha-
sized on differences with the normal samples. We believe that
the increased mitochondrial protein acetylation found in the
SNP carriers that had similar expression levels of SIRT3 to the
noncarriers (Figure 7B) supports a role for this SNP in PAH path-
ogenesis, over and above the role of a primary decrease in SIRT3
expression.
iPAH patients do not have known associated disorders that
predispose them to the disease, unlike aPAH patients, where
the presence of associated triggers (including inflammation in
scleroderma or increased pulmonary flow in congenital heart
disease) could independently explain the development of PAH.
In iPAH patients, SIRT3 inhibition could potentially explain
many aspects of the disease. We did not find increased pres-
ence of the SNP in aPAH, in contrast to our hypothesis that its
presence would make these patients predisposed to PAH.
Larger studies will be needed, including genotyping patients
with collagen vascular disease with and without PAH, in order
to understand the exact role of this SNP in the risk for aPAH.
Nevertheless our data support the view that despite similarities
in lung histology, the molecular backgrounds of iPAH and
aPAH may be different.
Of the seven members of the mammalian SIRT family, SIRT3,
4, and 5 are expressed in the mitochondria (Michishita et al.,
2005).Mice lackingSirt3 exhibit a high level of mitochondrial pro-
tein acetylation, whereas lack of Sirt4 or Sirt5 causes no change,
suggesting that SIRT3 is the major mitochondrial deacetylase
(Lombard et al., 2007). Thus, the increased mitochondrial acety-
lation of our animal and humanPAH tissues is likelymostly due to
suppressed SIRT3 activity. Our mechanistic in vitro experiments
allowed us to suggest that many critical factors previously linked
to the pathogenesis of PAH (e.g., mitochondrial hyperpolar-
ization, PDH inhibition, and NFAT-HIF1a-STAT3 activation)
may have a common origin and may all be downstream of anetabolism 20, 827–839, November 4, 2014 ª2014 Elsevier Inc. 835
Figure 7. The Presence of the SIRT3 Loss-of-Function SNP rs11246020 Is Associated with Clinical Idiopathic Pulmonary Arterial
Hypertension
(A) Table and graphical representation of the SNP rs11246020 frequency in an unbiased cohort of patients with iPAH, aPAH, or noPAH control patients. GG
corresponds to the normal alleles (green), AG to SNP heterozygosity (HET yellow), and AA to SNP homozygosity (HOMblue). Pearson chi-square test: ***p < 0.001
for association between the presence of SNP and iPAH.
(B and C) SIRT3 mRNA level in noPAH, aPAH, and iPAH human samples. Western blots for SIRT3 and acetylated lysine residues performed on isolated mito-
chondria from noPAH and iPAH lung samples, previously genotyped for SIRT3 polymorphism, and for which the histology (C) is proving the presence of classic
PAH pathology (H&E staining). SIRT3 expression and acetyl-lysine levels for each patient were normalized to the levels of COX4 (p < 0.001).
(D) Schematic of the potential role of SIRT3 downregulation and/or activity inhibition due to SIRT3 SNP in the pathogenesis of PAH (see Discussion).
Error bars represent SEM.
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Insight into the Metabolic Basis of PAHinhibition of the SIRT3 axis in mitochondria (Figure 7D). An
unexplored aspect of our data includes the effects of Sirt3 on
mitochondrial network dynamics (Samant et al., 2014). Since
mitochondrial biogenesis and fusion/fission are dysregulated in
PAH (Archer, 2013; Marsboom et al., 2012; Ryan et al., 2013),
more work is needed to explore the possibility that this mecha-
nism contributes to the development of spontaneous PAH in
Sirt3KO mice.
We present preliminary evidence that PGC-1a is at least in part
responsible for the downregulation of Sirt3 expression in human
iPAH-PASMC or in MCT-PAH, but additional factors like NF-kB
and Sp1 could play a role (Bellizzi et al., 2007).
A recent report byWaypa et al. failed to show the development
of PAH in Sirt3KOmice (Waypa et al., 2013). We believe that this
conflict is due to the different genetic background of the mice836 Cell Metabolism 20, 827–839, November 4, 2014 ª2014 Elsevierused in the two studies. The 129/Sv strain in our study (and in
which the KO was originally established [Lombard et al., 2007])
has been described to have higher serum glucose levels,
decreased metabolism, and decreased spontaneous activity
compared to the C57BL/6 (Funkat et al., 2004) strain in which
Waypa et al. backcrossed the original KO strain. We directly
compared resistance PASMC and lungs from the two WT mice
strains. We found lower SIRT3 expression, lower respiration
rates, higher DJm, as well as higher proliferation rates and
increased resistance to apoptosis after serum starvation in
129Sv compared to C57BL/6 PASMC (Figure S6). This suggests
that the deletion of a gene affecting the metabolism, like SIRT3,
may have a bigger impact on 129/Sv cells that have an already
slowermetabolism andmore suppressedmitochondrial function
than on C57BL/6; and this may partially explain the differencesInc.
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following a molecular or pharmacologic intervention are well
described between these two mice strains. For example, the
degree of hypertension, left ventricular hypertrophy, and glomer-
ulosclerosis following treatment with deoxycorticosterone was
most prominent in 129/Sv compared to C57BL/6 mice (Hartner
et al., 2003). A potential explanation is the number of renin genes:
129/Sv mice harbor two renin genes (Ren-1d and Ren-2), while
C57BL/6 mice have one renin gene (Ren-1c) (Wang et al.,
2002). The fact that the renin angiotensin system is involved in
Sirt3 axis regulation (Benigni et al., 2009), pulmonary hyperten-
sion (Morrell et al., 1995), and HIF-1a stabilization (Lauzier
et al., 2007) may also explain the differences observed between
us and Waypa et al.
Although we were more rigorous in our assessment of PAH in
these mice (compared to the Waypa report, which did not
include mean PA pressure measurements invasively or exercise
performance and did not systematically study the molecular
phenotype of PASMC), we believe strain differences are the
basis for our conflicting results. Our description of downregula-
tion of SIRT3 in both a rat PAH model and in actual patient tis-
sues offers a much more robust exploration of the role of
SIRT3 in this complex disease.
It is possible that patients with PAH have differences similar to
those described between the 129/Sv and the C57BL/6 mice
strains. In such a case the 129/Sv-like patients with more sup-
pressed mitochondrial function will be more sensitive to the
loss of SIRT3 and more likely to develop PAH. In fact it is known
that polymorphisms in mitochondrial DNA categorize humans in
several haplotype groups with different mitochondrial function,
as these polymorphisms affect the function of critical ETC
complexes. The differences between our mice and the mice
used by Waypa et al. may relate to real-life variability in human
populations in terms of metabolism and susceptibility to PAH
in response to loss of SIRT3 function.
The fact that the Sirt3KO mice not only exhibit a spontaneous
increase in PA pressures, but also develop proliferative
vascular remodeling and the full molecular phenotype in vitro,
as well as the recently described skeletal muscle metabolic
syndrome-like abnormalities, suggests that mice lacking Sirt3
may be a model of human PAH. We recently showed that
loss of the uncoupling protein 2 (UCP2) also causes sponta-
neous PAH in mice (Dromparis et al., 2013). UCP2 conducts
Ca2+ into the PASMC mitochondria and Ucp2KO-PASMCs
have decreased mitochondrial Ca2+. As many mitochondrial
enzymes (including PDH) are highly calcium-dependent, loss
of UCP2 leads to mitochondrial suppression, similar to loss of
SIRT3. As the parallels between PAH and cancer are increas-
ingly reported, it is intriguing that both the Ucp2- and Sirt3KO
mice are predisposed to cancer (Allison and Milner, 2007; Der-
da´k et al., 2006). In addition, SNPs of both genes are associ-
ated with metabolic syndrome in humans (Hirschey et al.,
2011; Shen et al., 2006).
This discussion is in keeping with the fact that PAH is rare and
supports the commonly accepted ‘‘multiple hit’’ hypothesis for
its pathogenesis. For example, a SIRT3 SNP, a UCP2 SNP,
and inflammation or other genetic and environmental factors
(like BMPR2 mutations) may all be required before a given pa-
tient may start developing the disease.Cell MLast, the fact that the young mice we studied did not have
evidence of a systemic vasculopathy (despite the global gene
deletion, also like the Ucp2KO mice) may relate to the fact that
the pulmonary circulation (which has different embryology than
the systemic circulation) may be more sensitive to a mitochon-
drial disturbance (Michelakis et al., 2002). Also, the resistance
pulmonary arteries exist at a much more oxidative stress state
(being exposed to pO2 of 120 mmHg, compared to the sys-
temic vessels being exposed to arterial PO2 50 mmHg) sug-
gesting different mitochondrial responses to oxidative stress.
Therefore, targeting the disturbed mitochondrial axis may pro-
vide relatively selective therapies, sparing the systemic vessels,
which is an essential feature of an ideal PAH therapy.
Our work supports the theory suggesting that the PAH syn-
drome has a mitochondrial/metabolic basis, at least in some
patients, and identifies SIRT3 as a potential therapeutic target.
It also illustrates the potential for a personalized medicine
approach where the presence of an SNP may identify patients
as best candidates for SIRT3 enhancement therapy, as small
molecule activators of SIRTs are in development.
EXPERIMENTAL PROCEDURES
All experiments performed were approved by the University of Alberta Com-
mittees on Animal Policy and Welfare and Human Ethics. Data are presented
as mean with error bars representing SEM. For comparison of two means, we
used a paired t test. For comparison betweenmore than twomeans, we used a
one-way ANOVA followed by a Tukey post hoc test. To study the association of
the SNP with the susceptibility to PAH we used a Pearson chi-square test. All
analyses were performed using SPSS 21 (IBM). p < 0.05 is indicated by * (or #),
p < 0.01 by ** (or ##), and p < 0.001 by *** (or ###).
Cell Culture
PASMCs from five Sirt3WT- or Sirt3KO-mice were isolated from fourth gener-
ation pulmonary arteries with an enzymatic cocktail containing papain (1 mg/
ml) (Sigma Aldrich), dithiothreitol (0.5 mg/ml) (Sigma Aldrich), collagenase
(0.6 mg/ml) (Worthington), and BSA (0.6 mg/ml) (Sigma Aldrich) and pooled
as previously described (Bonnet et al., 2007b). All PASMCs cell lines were
grown in Dulbecco’s Modified Eagle’s Medium (GIBCO) supplemented with
10% fetal bovine serum (Sigma Aldrich) and 1% antibiotic/antimycotic
(GIBCO) and placed in a humidified incubator set at 37C in either normoxic
conditions (21% O2; pO2 120 mmHg [pH 7.4]) or hypoxic conditions (4%
O2; pO2 40 mmHg [pH 7.4]). All cells were used until the fifth passage.
Animals
Mice were purchased from Jackson Laboratory (http://jaxmice.jax.org/),
but originally created by (Lombard et al., 2007). 250–350 g Sprague-Dawley
rats were injected subcutaneously with 60 mg/kg1 of monocrotaline MCT
to create PAH (Sigma Aldrich) (n = 20). Intratracheal deliveries of adenovi-
ruses carrying Sirt3+GFP or GFP alone were performed on day 21 postMCT
injection, once PAH was established, as described (McMurtry et al., 2005).
Rats were anesthetized with ketamine (75%) xylazine (15%) and intubated.
We used the Aeroneb Lab nebulizer (Aerogen) coupled to a Flexivent appa-
ratus (Scireq) to mechanically control pulmonary ventilation and volume
during nebulization. A total of 3 3 109 pfu were nebulized in 50 ml of normal
saline.
Hemodynamic Measurements
Rats and mice were initially anesthetized with 3%–4% isoflurane and main-
tained with 2% during procedures. All rodents underwent hemodynamic and
echocardiographic studies as previously described (Bonnet et al., 2007b). A
modified Millar catheter (microtip, 1.4F, Millar Instruments) was advanced
through the jugular vein in close-chest animals into the PA, and mean PA
pressure (mPAP) was recorded (Power Lab, with Chart software 5.4,etabolism 20, 827–839, November 4, 2014 ª2014 Elsevier Inc. 837
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Insight into the Metabolic Basis of PAHADInstruments), as previously described (Bonnet et al., 2007b). Cardiac output
(CO) was assessed by echocardiography using the Vevo770 imaging system
with a 707B (30 MHz for mice) or a 716 (70.5 MHz for rats) probe. The cardiac
output was calculated after determining the left ventricular outflow tract diam-
eter (LVOT), aortic velocity time integral (AoVTI), and heart rate (HR) using the
formula: CO = 7.85 3 LVOT2 3 AoVTIxHR/1,000. Total pulmonary resistance
was calculated as: mPAP/CO.
SNP Genotyping Assay
Genomic DNA was extracted from buffy coat using Allprep RNA/DNA kits
(QIAGEN). DNA samples were quantified with a Nanodrop Spectrophotometer
(ND-8000) and normalized to a concentration of 50 ng/ml (diluted in 10mMTris/
1 mM EDTA). Samples were genotyped by TaqMan SNP Genotyping Assays
and processed in triplicates according to the standard protocol with an ABI
Prism 7900 Sequence Detector (Applied Biosystems).
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